

Prediabetes & Type 2 Diabetes

EVIDENCE2PRACTICE ONTARIO (E2P) EMR TOOL FOR OSCAR PRO

Purpose of the tool:

- ✓ Support the early identification of patients at risk
- ✓ Facilitate the creation of tailored care plans
- ✓ Monitor and assess glycemic targets
- ✓ Provide patient education and coaching resources

Installation guide

User guide

Features of this tool include:

Prevention and management

Identifying and flagging pre-diabetic patients while monitoring patient response to treatment for type 2 diabetes through pharmacological therapies.


Screening and assessment

Assists in screening for risk factors, diagnoses, and complications for prediabetes and diabetes using standardized testing.


Support for patients

Enables identification of self-management therapies and streamlined navigation of available services and supports, tailored to individual patient needs.

Screenshot from the management module



Screenshot from the patient care plan module



Goals

It is helpful to plan out your goals. Using a plan can help give you a sense of direction, and help you organize and reach your goals.

Patient Goals

Lifestyle changes & Therapy

2023-05-10 ALOGLIPTIN 12.5 MG-METFORMIN 1,000 MG TABLET 1000mg once per day

Allergies

PENTAZOCINE, PINE NUT, CODEINE

Medications

Medication	Action	Notes
	Action	

Follow-up and next steps



Get started

To sign up or to learn more, please visit www.E2P.ca or scan the QR code.

Services available at no cost

Change management:

Enables smooth adoption and effective utilization of the E2P diabetes tool

- Tailored coaching and support for primary care clinicians, allied health professionals and all clinic staff
- Facilitated installation, set-up and tool training
- Review of existing workflows to maximize efficiencies

Academic detailing:

1-on-1 discussions with a trained clinical pharmacist to support clinician educational needs and build capacity and confidence to deliver best patient care, including:

- Transitioning patients on brand-name insulin glargine, aspart, or lispro, to a biosimilar brand insulin
- Considering factors beyond A1C lowering, when selecting non-insulin pharmacotherapy

Accessible. Actionable. Adaptable.

E2P brings together multi-disciplinary, cross-sector expertise under the joint leadership of the [Centre for Effective Practice](#), [eHealth Centre of Excellence](#), and [North York General Hospital](#). Funding and strategic guidance for E2P is provided by Ontario Health in support of Ontario's Digital First for Health Strategy.